Mucosal administration of apoB peptides, as well as subcutaneous injection of apoB peptides with or without aluminum-based adjuvants, have all been shown to inhibit atherosclerosis in experimental models through the activation of Tregs [53,54,55]. The gene discussed is APOB; the disease is atherosclerosis.